Log in

NASDAQ:LQDA - Liquidia Technologies Stock Price, Forecast & News

$4.93
+0.28 (+6.02 %)
(As of 03/31/2020 06:00 AM ET)
Today's Range
$4.48
Now: $4.93
$4.99
50-Day Range
$3.31
MA: $4.49
$6.04
52-Week Range
$2.65
Now: $4.93
$11.90
Volume81,075 shs
Average Volume105,081 shs
Market Capitalization$139.86 million
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. It has collaboration agreements with GlaxoSmithKline plc and the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina.
Read More
Liquidia Technologies logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LQDA
CUSIPN/A
CIKN/A
Phone919-328-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.07 million
Book Value$1.24 per share

Profitability

Net Income$-47,580,000.00

Miscellaneous

EmployeesN/A
Market Cap$139.86 million
Next Earnings Date5/7/2020 (Estimated)
OptionableNot Optionable

Receive LQDA News and Ratings via Email

Sign-up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter.


Liquidia Technologies (NASDAQ:LQDA) Frequently Asked Questions

How has Liquidia Technologies' stock been impacted by COVID-19 (Coronavirus)?

Liquidia Technologies' stock was trading at $3.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LQDA shares have increased by 34.7% and is now trading at $4.93. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Liquidia Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Liquidia Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Liquidia Technologies.

When is Liquidia Technologies' next earnings date?

Liquidia Technologies is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Liquidia Technologies.

How were Liquidia Technologies' earnings last quarter?

Liquidia Technologies Inc (NASDAQ:LQDA) posted its earnings results on Wednesday, March, 11th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.09. View Liquidia Technologies' earnings history.

What price target have analysts set for LQDA?

2 brokers have issued 1 year target prices for Liquidia Technologies' stock. Their forecasts range from $30.00 to $37.00. On average, they expect Liquidia Technologies' stock price to reach $33.50 in the next twelve months. This suggests a possible upside of 579.5% from the stock's current price. View analysts' price targets for Liquidia Technologies.

What are Wall Street analysts saying about Liquidia Technologies stock?

Here are some recent quotes from research analysts about Liquidia Technologies stock:
  • 1. According to Zacks Investment Research, "Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States. " (3/20/2020)
  • 2. Wedbush analysts commented, "We base our $27 price target on a sum-of-the-parts analysis derived from: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year-end 2019 fully diluted net cash of $2.03/share to arrive at our price target. We value the current commercial business at $12.94 per share and the pipeline at $11.99 per share. The commercial business value is based on a P/E multiple assumption of 30x our 2024E EPS of $0.75, discounted at 15%." (6/28/2019)

Has Liquidia Technologies been receiving favorable news coverage?

News coverage about LQDA stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Liquidia Technologies earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutLiquidia Technologies.

Are investors shorting Liquidia Technologies?

Liquidia Technologies saw a decline in short interest in March. As of March 13th, there was short interest totaling 552,100 shares, a decline of 15.0% from the February 27th total of 649,500 shares. Based on an average daily trading volume, of 78,500 shares, the short-interest ratio is currently 7.0 days. Approximately 3.7% of the company's stock are sold short. View Liquidia Technologies' Current Options Chain.

Who are some of Liquidia Technologies' key competitors?

What other stocks do shareholders of Liquidia Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia Technologies investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), vTv Therapeutics (VTVT), Vaxart (VXRT), Aytu Bioscience (AYTU), Nabriva Therapeutics (NBRV), TrovaGene (TROV), Zynerba Pharmaceuticals (ZYNE) and Protalix Biotherapeutics (PLX).

Who are Liquidia Technologies' key executives?

Liquidia Technologies' management team includes the following people:
  • Mr. Neal F. Fowler, CEO & Director (Age 57)
  • Mr. Robert A. Lippe, Chief Operations Officer (Age 54)
  • Mr. William R. Kenan Jr., Co-Founder
  • Dr. Ginger Denison, Co-Founder
  • Mr. Timothy M. Albury, Interim Chief Financial Officer (Age 50)

When did Liquidia Technologies IPO?

(LQDA) raised $50 million in an initial public offering (IPO) on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is Liquidia Technologies' stock symbol?

Liquidia Technologies trades on the NASDAQ under the ticker symbol "LQDA."

How do I buy shares of Liquidia Technologies?

Shares of LQDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Liquidia Technologies' stock price today?

One share of LQDA stock can currently be purchased for approximately $4.93.

How big of a company is Liquidia Technologies?

Liquidia Technologies has a market capitalization of $139.85 million and generates $8.07 million in revenue each year. The company earns $-47,580,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.  View additional information about Liquidia Technologies.

What is Liquidia Technologies' official website?

The official website for Liquidia Technologies is http://www.liquidia.com/.

How can I contact Liquidia Technologies?

Liquidia Technologies' mailing address is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. The company can be reached via phone at 919-328-4400 or via email at [email protected]


MarketBeat Community Rating for Liquidia Technologies (NASDAQ LQDA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about Liquidia Technologies and other stocks. Vote "Outperform" if you believe LQDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LQDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel